Business Wire

ADVA unveils new DCI OLS for the 400ZR era

30.3.2021 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today launched its new FSP 3000 data center interconnect (DCI) open line system (OLS) specifically designed for 400ZR technologies. The new DCI OLS addresses the most urgent challenges for network operators by enabling commercial deployments of DCI infrastructure based on 400ZR. These high-density, cost-effective, open solutions that are optimized for point-to-point applications up to 120km will be key to rapidly expanding DCI capacity to meet soaring data demand. Currently undergoing customer testing and evaluation, the ADVA DCI OLS has demonstrated seamless interoperability with 400ZR pluggable transceivers. The solution is fully compliant and even outperforms the 400ZR standard. What’s more, with data center-compatible open APIs, it can be directly integrated into SDN environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005055/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s new DCI OLS will be pivotal to unlocking the full potential of 400ZR (Photo: Business Wire)

“Today we’re announcing a major milestone for open, high-capacity data center networks. The launch of our new DCI OLS will be key for operators. It provides the missing link to real-world deployments of open infrastructure built with 400ZR interfaces,” said Christoph Glingener, CTO, ADVA. “Our pedigree in the DCI space is second to none. We were the original DCI company, enabling Fortune 500 companies around the globe to harness the cloud with best-in-breed solutions. For more than 25 years, our innovation has helped the industry evolve. Now we’re giving large-scale DCI providers what they need to move forward. Our next-generation FSP 3000 DCI OLS offers a way to inject ultra-high capacity while reducing total cost of ownership and operational complexity. What’s more, the ADVA FSP 3000 DCI OLS solution is designed to optimize performance with 400ZR-compliant optics from any vendor.”

The ADVA FSP 3000 DCI OLS is fully compliant with the OIF’s implementation agreement for 400ZR coherent optical interfaces. Optimized for amplified 400Gbit/s DWDM links with reaches up to 120km at 75GHz or 100GHz channel spacing, the solution exceeds all 400ZR performance specifications. It’s also compatible with OpenZR+ interfaces, which expand the application area to DCI applications with distances far beyond 120km. With its open interfaces, the ADVA DCI OLS ensures seamless integration with third-party transceivers and enables network operators to deploy best-of-breed technology. A high level of functional integration minimizes fiber cabling and provides simplified, automated and rapid turnup for optimal performance. The ADVA FSP 3000 DCI OLS integrates multiple diagnostic tools, including built-in OTDR for the monitoring of all fibers and built-in optical channel monitoring. These automated diagnostic capabilities significantly reduce operating costs and improve repair time.

“Omdia is projecting a significant market take-up for 400ZR pluggable technology. 400ZR has many appealing attributes, including multi-vendor interoperability, appealing cost per bit, and a small form factor with low power consumption. Additionally, 400ZR will be practically deployable in switch/routing platforms, enabling the realization of a decades-long service provider dream,” commented Ian Redpath, practice leader, transport networks and components, Omdia. “ADVA has a proven co-development track record in supporting open and innovative DCI solutions. With its new DCI OLS, ADVA is ideally positioned to take the open line system concept to the next level, interworking directly with 400ZR. And with open API support, ADVA will ensure tight integration with cloud and network provider SDN orchestration and control systems.”

Watch this video for more information on the new DCI OLS: https://youtu.be/8zI3E46oMBo.

Further details are also available in these slides: https://adva.li/dci-ols-400zr-slides.


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye